Sector News

In regional shakeup, Novartis’ Alcon fires two Asia execs

June 12, 2015
Life sciences
Two key executives of Novartis subsidiary Alcon with responsibility for Asia were fired this week, AsianScientist reported, after confirming the action by the parent company.
 
Roy Acosta, Asia & Russia region president, and Jim West, Asia & Russia chief financial officer, of global medical company Alcon were fired on June 10, AsianScientist said, noting that Novartis declined to discuss the reasons for the move.
 
In an email response, Novartis confirmed to FiercePharmaAsia that the two executives had left the company.
 
“Novartis can confirm that Roy Acosta, Region President, Asia & Russia, and Jim West, Chief Financial Officer, Asia & Russia, will be leaving the company after 25 years of service, respectively,” a company spokesman said in an email.
 
Eric Van Oppens, who is currently head of the Asia cluster for Novartis Pharma, will replace Acosta as Asia & Russia region president at Alcon, effective July 1, the spokesperson said.
 
Oppens, who is currently head of the Asia Cluster for Novartis Pharma, has been appointed as region president, Asia & Russia at Alcon, effective July 1.
 
Acosta reported directly to Jeff George, head of Alcon and member of the executive committee of Swiss-based Novartis.
 
Alcon, which makes sterile eye care products and operates out of Fort Worth, Texas, is the second-largest division of Novartis; it was bought in 2011 for $51.9 billion.
 
AsianScientist said that Acosta joined Alcon in 1989 and has held various leadership positions within U.S. and International Operations, citing his biography on the company’s website.
 
Alcon faced accusations in 2013 of diverting funds meant for postmarketing surveys to bribe doctors in China.
 
Novartis faced sales sanctions and investigations by regulators last year in Japan over failure to report serious side effects during clinical trials as well as complaints that sales officials had an indirect role in managing data.
 
AsianScientist said a spokesperson for Novartis Media Relations in Basel confirmed that Acosta and West were let go on Wednesday.
 
By EJ Lane
 

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach